perphenazine Side Effects
Also known as: Trilafon
Analysis of 2,013 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
2,013
Death-Related
221
11.0% of reports
Hospitalizations
971
48.2% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 221 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| COMPLETED SUICIDE | 87 |
| TOXICITY TO VARIOUS AGENTS | 53 |
| DEATH | 39 |
| CARDIAC ARREST | 29 |
| BRADYCARDIA | 17 |
| ATRIOVENTRICULAR BLOCK | 14 |
| SEIZURE | 14 |
| HYPOTENSION | 13 |
| SOMNOLENCE | 13 |
| DYSPNOEA | 10 |
| INTENTIONAL OVERDOSE | 10 |
| BRAIN OEDEMA | 9 |
| OVERDOSE | 9 |
| CONFUSIONAL STATE | 7 |
| FALL | 7 |
| HYPERAMMONAEMIC ENCEPHALOPATHY | 7 |
| BRAIN HERNIATION | 6 |
| CARDIO-RESPIRATORY ARREST | 6 |
| DRUG INEFFECTIVE | 6 |
| HEPATOMEGALY | 6 |
Reactions in Hospitalization Reports
Top reactions in 971 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DRUG INEFFECTIVE | 263 |
| TOXICITY TO VARIOUS AGENTS | 230 |
| WEIGHT INCREASED | 179 |
| SUICIDE ATTEMPT | 175 |
| AKATHISIA | 166 |
| OBSESSIVE-COMPULSIVE DISORDER | 152 |
| INCREASED APPETITE | 151 |
| EUPHORIC MOOD | 150 |
| ANTIPSYCHOTIC DRUG LEVEL BELOW THERAPEUTIC | 148 |
| DISINHIBITION | 148 |
| THERAPEUTIC PRODUCT EFFECT INCOMPLETE | 140 |
| THERAPEUTIC PRODUCT EFFECT VARIABLE | 139 |
| PRODUCT USE IN UNAPPROVED INDICATION | 137 |
| LEUKOPENIA | 129 |
| OFF LABEL USE | 123 |
| DRUG INTERACTION | 93 |
| HYPERTENSION | 90 |
| LEUKAEMIA | 82 |
| FALL | 80 |
| OBESITY | 75 |
Nearby — Related Medications
What the FAERS Data Reveals About perphenazine Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 2,013 voluntary reports linked to perphenazine and its brand equivalents (Trilafon), spanning 2004 through 2025. Of those, 221 (11.0%) listed death as an outcome and 971 (48.2%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 56% were female and 44% male; age distribution skews toward 18-44, with 528 reports in that bracket. The single most reported reaction is drug ineffective with 357 submissions, followed by toxicity to various agents and weight increased.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.